Nuclera Extends Series C Funding to $87 Million to Advance Antibody Engineering

Nuclera, the biotechnology company accelerating drug discovery by providing rapid, easy access to functional proteins through its benchtop eProtein Discovery™ System, led by Michael Chen, Gordon Mcinroy, and others, announced a USD $12 million financing extension, bringing the Company’s total Series C funding to USD $87 million, led by Elevage Medical Technologies and Jonathan Milner, joined by existing investors British Business Bank and GK Goh.

The investment will accelerate integration of antibody expression and binding validation into the company’s eProtein Discovery benchtop system, enabling in-house multiplex protein screening, characterization, and expression.

The expansion adds antibody-specific capabilities to eProtein Discovery, enabling end-to-end expression, purification, and binding validation on one high-throughput system while supporting AI-driven protein engineering with standardized, scalable datasets.

Since its 2024 Series C raise, the company has expanded eProtein Discovery with a membrane protein workflow, grown its global presence across APAC and the Middle East, and partnered with Cytiva to accelerate DNA-to-protein characterization. The system was also deployed at Domainex, its first CRO installation, streamlining protein production and reinforcing its commercial and scientific value.

Dr. Michael Chen emphasized that the new financing strengthens Nuclera’s momentum as eProtein Discovery expands into AI-driven biologics R&D, providing scalable, high-quality datasets for faster therapeutic development.

Dr. Michael Wasserman noted significant progress in platform capabilities and global adoption, with full-format antibody expression and validation representing a major step forward for AI-enabled discovery workflows.

Dr. Jonathan Milner highlighted Nuclera’s ability to remove key bottlenecks in antibody synthesis, leveraging success in membrane proteins and microfluidics to transform antibody development processes.

By combining proprietary cell-free expression, digital microfluidics, and high-fidelity screening data, eProtein Discovery identifies the most promising protein candidates early in the process, dramatically reducing the time, cost, and uncertainty typically associated with expression and purification.

Taylor Wessing LLP served as legal advisor to Nuclera for the financing.